AstraZeneca PLC (AZN) revenue by segment
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
Doanh thu theo bộ phận của AstraZeneca PLC
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tagrisso | – | – | – | – | $5.02B | $4.33B | $3.19B | $1.86B | $955.00M | $423.00M | – | – |
| Onglyza | – | – | – | – | $360.00M | $470.00M | $527.00M | $543.00M | $611.00M | $720.00M | – | – |
| Arimidex | – | – | – | – | $139.00M | $185.00M | $225.00M | $212.00M | $217.00M | $232.00M | – | – |
| Atacand | – | – | – | – | $97.00M | $243.00M | $221.00M | $260.00M | $300.00M | $315.00M | – | – |
| Brilinta | – | – | – | – | $1.47B | $1.59B | $1.58B | $1.32B | $1.08B | $839.00M | – | – |
| Bydureon | – | – | – | – | $385.00M | $448.00M | $549.00M | $584.00M | $574.00M | $578.00M | – | – |
| Byetta | – | – | – | – | $55.00M | $68.00M | $110.00M | $126.00M | $176.00M | $254.00M | – | – |
| Casodex | – | – | – | – | $143.00M | $172.00M | $200.00M | $201.00M | $215.00M | $247.00M | – | – |
| Crestor | – | – | – | – | $1.10B | $1.18B | $1.28B | $1.43B | $2.37B | $3.40B | – | – |
| Daliresp/Daxas | – | – | – | – | $227.00M | $217.00M | $215.00M | $189.00M | $198.00M | $154.00M | – | – |
| Farxiga | – | – | – | – | $3.00B | $1.96B | $1.54B | $1.39B | $1.07B | $835.00M | – | – |
| Faslodex | – | – | – | – | $431.00M | $580.00M | $892.00M | $1.03B | $941.00M | $830.00M | – | – |
| Iressa | – | – | – | – | $183.00M | $268.00M | $423.00M | $518.00M | $528.00M | $513.00M | – | – |
| Losec/Prilosec | – | – | – | – | $180.00M | $183.00M | $263.00M | $272.00M | $271.00M | $276.00M | – | – |
| Lynparza | – | – | – | – | $2.35B | $1.78B | $1.20B | $647.00M | $297.00M | $218.00M | – | – |
| Nexium | – | – | – | – | $1.33B | $1.49B | $1.48B | $1.70B | $1.95B | $2.03B | – | – |
| Total Oncology | – | – | – | – | $13.05B | $10.85B | $8.67B | $6.03B | $4.02B | $3.38B | – | – |
| Other Oncology | – | – | – | – | $50.00M | $51.00M | $94.00M | $115.00M | $114.00M | $104.00M | – | – |
| Total Other medicines | – | – | – | – | $2.37B | $2.59B | $2.60B | $3.40B | $4.16B | $5.07B | – | – |
| Other, Others | – | – | – | – | $106.00M | $126.00M | $193.00M | $290.00M | $738.00M | $920.00M | – | – |
| Other R&I | – | – | – | – | $594.00M | $398.00M | $467.00M | $545.00M | $433.00M | $316.00M | – | – |
| Pulmicort | – | – | – | – | $962.00M | $996.00M | $1.47B | $1.29B | $1.18B | $1.06B | – | – |
| BioPharmaceuticals: total Respiratory & Immunology | – | – | – | – | $6.03B | $5.36B | $5.39B | $4.91B | $4.71B | $4.75B | – | – |
| Seloken/Toprol-XL | – | – | – | – | $951.00M | $821.00M | $760.00M | $712.00M | $695.00M | $737.00M | – | – |
| Symbicort | – | – | – | – | $2.73B | $2.72B | $2.50B | $2.56B | $2.80B | $2.99B | – | – |
| Synagis | – | – | – | – | $410.00M | $372.00M | $358.00M | $665.00M | $687.00M | $677.00M | – | – |
| Zoladex | – | – | – | – | $948.00M | $888.00M | $813.00M | $752.00M | $735.00M | $816.00M | – | – |
| CVRM | – | – | – | – | $8.02B | $7.10B | $6.91B | $6.71B | $7.27B | $8.12B | – | – |
| CVRM, Others | – | – | – | – | $196.00M | $191.00M | $271.00M | $301.00M | $339.00M | $437.00M | – | – |
| Seroquel XR/IR | – | – | – | – | $92.00M | $117.00M | $191.00M | $361.00M | $508.00M | $967.00M | – | – |
| Bevespi | – | – | – | – | $54.00M | $48.00M | $42.00M | $33.00M | $16.00M | – | – | – |
| Imfinzi | – | – | – | – | $2.41B | $2.04B | $1.47B | $633.00M | $19.00M | – | – | – |
| Calquence | – | – | – | – | $1.24B | $522.00M | $164.00M | $62.00M | $3.00M | – | – | – |
| Fasenra | – | – | – | – | $1.26B | $949.00M | $704.00M | $297.00M | $1.00M | – | – | – |
| Other diabetes | – | – | – | – | $59.00M | $47.00M | $52.00M | $39.00M | $53.00M | – | – | – |
| Breztri | – | – | – | – | $203.00M | $28.00M | $2.00M | – | – | – | – | – |
| Lokelma | – | – | – | – | $175.00M | $76.00M | $14.00M | – | – | – | – | – |
| FluMist | – | – | – | – | $253.00M | $295.00M | $113.00M | – | – | – | – | – |
| Koselugo | – | – | – | – | $108.00M | $38.00M | – | – | – | – | – | – |
| COVID 19 | – | – | – | – | $4.00B | $2.00M | – | – | – | – | – | – |
| Vaxzevria | – | – | – | – | $3.92B | $2.00M | – | – | – | – | – | – |
| roxadustat | – | – | – | – | $174.00M | – | – | – | – | – | – | – |
| Enhertu | – | – | – | – | $17.00M | – | – | – | – | – | – | – |
| Total rare diseases | – | – | – | – | $3.07B | – | – | – | – | – | – | – |
| Saphnelo | – | – | – | – | $8.00M | – | – | – | – | – | – | – |
| Strensiq | – | – | – | – | $378.00M | – | – | – | – | – | – | – |
| Soliris | – | – | – | – | $1.87B | – | – | – | – | – | – | – |
| Evusheld | – | – | – | – | $85.00M | – | – | – | – | – | – | – |
| Andexxa | – | – | – | – | $68.00M | – | – | – | – | – | – | – |
| Orpathys | – | – | – | – | $16.00M | – | – | – | – | – | – | – |
| Kanuma | – | – | – | – | $62.00M | – | – | – | – | – | – | – |
| Ultomiris. | – | – | – | – | $688.00M | – | – | – | – | – | – | – |
| FluMist/Fluenz | – | – | – | – | – | $295.00M | $113.00M | $110.00M | $78.00M | $104.00M | – | – |
| Duaklir | – | – | – | – | – | – | $77.00M | $95.00M | $79.00M | $63.00M | – | – |
| Movantik/Moventig | – | – | – | – | – | – | – | $109.00M | $122.00M | $91.00M | – | – |
| Eklira/Tudorza | – | – | – | – | – | – | – | $110.00M | $150.00M | $170.00M | – | – |
| Symlin | – | – | – | – | – | – | – | $34.00M | $48.00M | – | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outside the UK | $54.38B | $49.33B | $42.44B | $41.23B | $34.17B | $24.88B | – | – | – | – | 92.6% | +10.2% |
| The Americas | $27.56B | $24.99B | $20.77B | $19.62B | $14.02B | $10.31B | $9.33B | $8.53B | $7.96B | $9.17B | 46.9% | +10.3% |
| United States | $23.97B | $21.81B | $18.12B | $17.28B | – | – | – | – | – | – | 40.8% | +9.9% |
| Rest of Europe | $13.46B | $11.70B | $9.73B | $8.91B | – | – | – | – | – | – | 22.9% | +15.0% |
| Asia, Africa And Australasia | $13.37B | $12.64B | $11.95B | $12.71B | $12.32B | $9.73B | $9.07B | $7.35B | $6.71B | $6.40B | 22.8% | +5.8% |
| China | $6.64B | $6.42B | $5.87B | $5.74B | $6.00B | $5.35B | $4.87B | $3.78B | $2.96B | $2.65B | 11.3% | +3.4% |
| United Kingdom | $4.36B | $4.74B | $3.37B | $3.12B | – | – | – | – | – | – | 7.4% | -8.0% |
| Others, Europe | $4.32B | $3.66B | $3.11B | $2.71B | $1.95B | $1.39B | – | – | – | – | 7.4% | +17.9% |
| Japan | $3.56B | $3.45B | $3.64B | $3.99B | $3.40B | $2.57B | $2.52B | $1.95B | $2.17B | $2.15B | 6.1% | +3.0% |
| Germany | $2.89B | $2.52B | $2.10B | $1.90B | $1.49B | $937.00M | $704.00M | $592.00M | $541.00M | $615.00M | 4.9% | +14.5% |
| Other Asia, Africa and Australasia excluding Australia, China and Japan | $2.72B | $2.33B | $2.05B | $2.41B | $2.38B | $1.53B | $1.42B | $1.31B | $1.21B | $1.22B | 4.6% | +16.8% |
| Other Americas excluding US and Canada | $2.63B | $2.25B | $1.68B | $1.18B | $1.20B | $761.00M | $814.00M | $806.00M | $809.00M | $846.00M | 4.5% | +17.2% |
| Sweden | $2.62B | $2.29B | $1.70B | $1.72B | $2.32B | $1.03B | $834.00M | $477.00M | $842.00M | $1.52B | 4.5% | +14.5% |
| France | $1.41B | $1.28B | $1.15B | $1.11B | $915.00M | $653.00M | $578.00M | $617.00M | $701.00M | $899.00M | 2.4% | +9.7% |
| Spain | $1.14B | $994.00M | $847.00M | $738.00M | $578.00M | $398.00M | $359.00M | $396.00M | $447.00M | $440.00M | 1.9% | +14.3% |
| Italy | $1.08B | $949.00M | $813.00M | $735.00M | $577.00M | $431.00M | $396.00M | $426.00M | $514.00M | $529.00M | 1.8% | +13.6% |
| Canada | $954.00M | $937.00M | $967.00M | $1.17B | $772.00M | $596.00M | $466.00M | $483.00M | $482.00M | $495.00M | 1.6% | +1.8% |
| Australia | $454.00M | $439.00M | $390.00M | $571.00M | $547.00M | $282.00M | $266.00M | $313.00M | $377.00M | $385.00M | 0.8% | +3.4% |
| UK | – | – | $3.37B | $3.12B | $3.25B | $1.74B | $1.82B | $2.39B | $3.24B | $1.85B | – | – |
| Europe | – | – | $9.73B | $8.91B | $7.83B | $4.84B | $4.16B | $3.82B | $4.56B | $5.58B | – | – |
| US | – | – | $18.12B | $17.28B | $12.05B | $8.96B | $8.05B | $7.24B | $6.67B | $7.83B | – | – |
| Emerging Markets | – | – | – | – | $12.16B | $8.68B | $8.17B | $6.89B | $6.15B | $5.79B | – | – |
| Rest of World | – | – | – | – | $4.78B | $3.51B | $3.30B | $2.82B | $3.08B | $3.10B | – | – |
| Other continental Europe excluding Belgium, France, Germany, Italy, Spain and Sweden | – | – | – | – | $1.95B | $1.39B | $1.29B | $1.31B | $1.51B | $1.58B | – | – |
| External | – | – | – | – | $34.17B | $24.88B | $22.56B | $19.70B | $19.23B | $21.15B | – | – |
| Intra-Group | – | – | – | – | – | – | – | – | $2.45B | $3.49B | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của AstraZeneca (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của AstraZeneca, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?